Nature Communications (Apr 2018)

Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1

  • Yinghua Zhu,
  • Yujie Liu,
  • Chao Zhang,
  • Junjun Chu,
  • Yanqing Wu,
  • Yudong Li,
  • Jieqiong Liu,
  • Qian Li,
  • Shunying Li,
  • Qianfeng Shi,
  • Liang Jin,
  • Jianli Zhao,
  • Dong Yin,
  • Sol Efroni,
  • Fengxi Su,
  • Herui Yao,
  • Erwei Song,
  • Qiang Liu

DOI
https://doi.org/10.1038/s41467-018-03951-0
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 11

Abstract

Read online

Most breast cancer patients are estrogen receptor positive and thus benefit from treatments that inhibit estrogen production; however, one third of tamoxifen-treated patients develops resistance and relapse. Here the authors show that tamoxifen resistant cells are resistant to chemotherapy because of BARD1 and BRCA1 upregulation.